ALCAM and neoplasm: By using the surface marker CD166 alone, flow cytometry analysis showed the presence of a variable fraction of CD166+ cell populations in 10 out of 10 tumor samples, varying from 0.01% to a maximum of 0.47% (Fig. 1a, Additional file 1 Table S1).